U.S., Aug. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07128342) titled 'CGM Use in Non-insulin Patients With DM2' on Aug. 12.
Brief Summary: The U.S. Food and Drug Administration (FDA) has approved multiple Continuous Glucose Monitoring (CGM) devices from different manufacturers to be used as an aide in patients with type 1 and type 2 diabetes who require medications, and more recently, as over the counter versions for patients with and or without diabetes who want to better understand how diet and exercise may impact blood sugar levels. However robust evidence supporting that CGM is significantly superior to traditional home fingerstick blood glucose monitoring (FSBGM) in this population is lacking. Th...